Sclerosis News and Research

RSS

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

Serono and IVAX Corporation has announced positive results from two clinical trials with a new proprietary oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS). The study results showed that the formulation of oral cladribine which has been developed by Serono and IVAX has met the targets for an orally administered product, with blood levels of cladribine in the expected therapeutic range. Efficacy studies of oral cladribine in MS patients are planned to start late 2004.

23 Mar 2004

New therapy for multiple sclerosis sufferers

Serono and IVAX Corporation have announced positive results from two clinical trials with a new proprietary oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS).

23 Mar 2004

£76 million research centre to make the UK a global centre of excellence for clinical imaging

GlaxoSmithKline (GSK) and Imperial College London today announce a unique research collaboration in medical imaging. GSK will contribute funding of £28m for the construction of a new Clinical Imaging Centre, next to Hammersmith Hospital in West London, UK. Research will focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis and psychiatric diseases. In association with the Clinical Imaging Centre, GSK and Imperial have entered into a 10-year research agreement for medical imaging.

22 Mar 2004